文献速递结核与非结核分枝杆菌

新型线性探针检测结核分枝杆菌吡嗪酰胺耐药性的评估

Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.
PubMed 文献 · Clin Microbiol Infect · 2017-06-03

该研究评估了新型Genoscholar PZA-TB II线性探针检测(PZA-LPA2)对吡嗪酰胺耐药的性能,以pncA Sanger测序和Illumina测序加表型药敏为复合参考标准,检测了87株来自WHO耐药监测的结核分枝杆菌分离株及59份痰标本。结果显示,对监测分离株的总体一致率为97.6%(排除异质性耐药)或94.3%(包含异质性耐药);在临床标本中,有效结果的灵敏度和特异度均为100%,但8.5%的标本检测失败。PZA-LPA2可作为间接药敏试验的快速替代方法,直接检测初步结果有前景。

要点

  • PZA-LPA2与复合参考标准的一致率在监测菌株中为97.6%(排除异质性耐药)或94.3%(包含异质性耐药)。
  • 临床痰标本直接检测失败率为8.5%(5/59),有效结果的灵敏度和特异度均为100%。
  • PZA-LPA2可作为吡嗪酰胺耐药的快速间接药敏替代方法,直接检测需进一步验证。

核心结论

  • PZA-LPA2是吡嗪酰胺耐药间接药敏试验的有效快速替代方法,直接检测临床标本初步结果有前景。

研究设计与样本

  • 研究评估新型Genoscholar PZA-TB II线性探针检测(PZA-LPA2),以pncA Sanger测序和Illumina测序加表型药敏为复合参考标准,检测87株来自WHO耐药监测的结核分枝杆菌分离株及59份痰提取物。

主要发现

  • 对监测分离株,PZA-LPA2与复合参考标准的总体一致率为97.6%(80/82,排除异质性耐药)或94.3%(82/87,包含异质性耐药)。
  • PZA-LPA2在8.5%(5/59)的临床标本中检测失败;有效结果相对于pncA Sanger测序的灵敏度和特异度均为100%(14/14和7/7)。

关键数值与推荐

  • PZA-LPA2对监测菌株的总体一致率:排除异质性耐药97.6%(80/82),包含异质性耐药94.3%(82/87)。
  • 临床标本检测失败率8.5%(5/59),有效结果灵敏度100%(14/14),特异度100%(7/7)。

临床怎么用

  • PZA-LPA2可用于结核分枝杆菌吡嗪酰胺耐药的快速间接药敏检测,直接检测痰标本需注意可能的检测失败。

局限性

  • 需进一步研究评估遗漏异质性耐药的临床风险以及假性检测谱系特异性、沉默和非关联突变的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The development of rapid molecular diagnostic assays for pyrazinamide (PZA) resistance is considered technically challenging as mutations are highly diverse, scattered along the full length of the pncA gene and not all are associated with PZA resistance. We evaluated the performance of the novel Genoscholar PZA-TB II line probe assay (PZA-LPA2; NIPRO Corporation, Japan). METHODS: To evaluate the applicability of the PZA-LPA2 in clinical settings, we compared the performance of the PZA-LPA2 to a composite reference standard pncA Sanger and Illumina sequencing plus phenotypic susceptibility testing on a panel of 87 Mycobacterium tuberculosis isolates from World Health Organization (WHO) drug resistance surveys, harbouring mutations previously classified as associated or not associated with resistance according to data from peer-reviewed literature. In addition, the PZA-LPA2 was challenged against a selection of isolates with lineage-specific and non-resistance-associated mutations, for which the frequency among clinical isolates is unknown, and tested directly on 59 sputum extracts. RESULTS: For the survey isolates, the PZA-LPA2 reached an overall agreement with the composite reference of 97.6% (80/82) or 94.3% (82/87) excluding or including heteroresistance, respectively. The PZA-LPA2 failed on 8.5% (5/59) of clinical samples; among valid results, 100% (14/14) sensitivity and 100% (7/7) specificity was reached relative to pncA Sanger sequencing. CONCLUSIONS: The PZA-LPA2 represents a valid and rapid alternative for indirect PZA susceptibility testing. Preliminary findings on clinical samples show promise for direct testing. Further studies are needed to assess the clinical risk of missing heteroresistance and falsely detecting lineage-specific, silent and nonassociated mutations.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Driesen M, Kondo Y, de Jong BC, et al. Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment. Clin Microbiol Infect. 2017. PMID: 28587904. doi:10.1016/j.cmi.2017.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。